- Trials with a EudraCT protocol (138)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
138 result(s) found for: Erythrocyte count.
Displaying page 1 of 7.
EudraCT Number: 2007-003479-37 | Sponsor Protocol Number: CER 06-167 | Start Date*: 2008-03-26 |
Sponsor Name:University Hospital of Geneva [...] | ||
Full Title: Efficacy of Methotrexate on Chronic Chondrocalcinosis | ||
Medical condition: Chronic Chondrocalcinosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000514-21 | Sponsor Protocol Number: AG-PH3 | Start Date*: 2007-01-02 |
Sponsor Name:CIS bio International | ||
Full Title: Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peri... | ||
Medical condition: Patients with suspected or documented osteomyelitis in the peripheral skeleton including patients with loosening of joint prosthesis or diabetic foot. At least one of following signs or symptoms is... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) HU (Completed) DE (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002156-27 | Sponsor Protocol Number: 1356/2015 | Start Date*: Information not available in EudraCT |
Sponsor Name:Medical University of Vienna | ||
Full Title: Prospective controlled study of reduced-dose Rituximab in rheumatoid arthritis patients in low disease activity and remission – the REDOREM study | ||
Medical condition: rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-000932-70 | Sponsor Protocol Number: APHP200067 | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS | |||||||||||||
Full Title: Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mismatch after allogeneic hematopoietic stem cell transplan... | |||||||||||||
Medical condition: Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000350-11 | Sponsor Protocol Number: 2032/MUL | Start Date*: 2014-05-28 | |||||||||||||||||||||
Sponsor Name:Multiplex Pharma Holdings LLC | |||||||||||||||||||||||
Full Title: An open label, randomized study to investigate the safety of weekly pentosan polysulfate injections in adult patients with Mucopolysaccharidosis Type I receiving enzyme replacement therapy. | |||||||||||||||||||||||
Medical condition: Mucopolysaccharidosis type I (alpha-L-Iduronidase deficiency) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002293-28 | Sponsor Protocol Number: 2020-002293-28 | Start Date*: 2020-05-29 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study | |||||||||||||
Medical condition: SARS-COV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002132-26 | Sponsor Protocol Number: WA18230 | Start Date*: 2008-02-19 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001682-42 | Sponsor Protocol Number: ML 20381 | Start Date*: 2006-07-16 |
Sponsor Name:Roche AB | ||
Full Title: Rituximab phase IIIb open-label, multi-centre assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor (RESET). | ||
Medical condition: Active reumathoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000482-35 | Sponsor Protocol Number: ARA102198 | Start Date*: 2004-10-11 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd. | ||
Full Title: A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000660-25 | Sponsor Protocol Number: CT-P17_3.2 | Start Date*: 2019-07-09 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis | |||||||||||||
Medical condition: Moderate to Severe Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005398-18 | Sponsor Protocol Number: W15-679 | Start Date*: 2016-07-12 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE) | |||||||||||||
Medical condition: Axial spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004715-22 | Sponsor Protocol Number: VX06-702-304 | Start Date*: 2006-10-26 |
Sponsor Name:Vertex Pharmaceuticals Incorporated | ||
Full Title: A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003009-31 | Sponsor Protocol Number: HH007 | Start Date*: 2022-12-23 | |||||||||||
Sponsor Name:Zealand University Hospital, dept. of Haematology | |||||||||||||
Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis | |||||||||||||
Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003830-17 | Sponsor Protocol Number: ACH228-110 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient... | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000549-13 | Sponsor Protocol Number: VX04-702-301 | Start Date*: 2005-05-03 |
Sponsor Name:Vertex Pharmaceuticals Incorporated | ||
Full Title: A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis | ||
Medical condition: rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003686-17 | Sponsor Protocol Number: I4V-MC-JADY | Start Date*: 2013-05-29 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) CZ (Prematurely Ended) BE (Completed) PL (Completed) SE (Completed) GB (Completed) HU (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) LV (Completed) LT (Completed) GR (Completed) SI (Completed) HR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000439-17 | Sponsor Protocol Number: 8457-008 | Start Date*: 2012-05-11 |
Sponsor Name:MERCK SHARP & DOHME CORP. | ||
Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerabil... | ||
Medical condition: active rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-021577-37 | Sponsor Protocol Number: ALT4864g | Start Date*: 2010-12-16 | |||||||||||
Sponsor Name:GENENTECH, Inc | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MLTA3698A IN COMBINATION WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) COMPARED WITH ADALIMU... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003053-21 | Sponsor Protocol Number: M16-560 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth... | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003508-36 | Sponsor Protocol Number: NP01-007 | Start Date*: 2008-06-17 | |||||||||||
Sponsor Name:Nitec Pharma AG | |||||||||||||
Full Title: A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
